TOP TEN perturbations for 38985_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38985_at
Selected probe(set): 202594_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38985_at (202594_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-3.5368252Number of Samples:3 / 5
Experimental | ovarian tumor study 16 |
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
Control | normal ovarian surface epithelial cell sample |
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-3.1106882Number of Samples:4 / 6
Experimental | F. tularensis study 1 (novicida) |
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.9333372Number of Samples:4 / 6
Experimental | F. tularensis study 1 (tularensis Schu S4) |
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
peptidoglycan study 1 / mock treated neonatal neutrophils
Relative Expression (log2-ratio):-2.86172Number of Samples:3 / 3
Experimental | peptidoglycan study 1 |
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours. | |
Control | mock treated neonatal neutrophils |
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours. |
ovarian tumor study 13 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-2.813302Number of Samples:18 / 12
Experimental | ovarian tumor study 13 |
Human epithelial tumor cell samples from the ovary of patients with serous adenocarcinoma. Samples were derived by laser capture microdissection (LCM). | |
Control | normal ovarian surface epithelial cell sample |
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from healthy donors. Samples were derived by cell surface brushing. |
ovarian tumor study 25 (serous ovarian cancer epithelium) / normal ovarian surface epithelium cell sample
Relative Expression (log2-ratio):-2.7323952Number of Samples:12 / 12
Experimental | ovarian tumor study 25 (serous ovarian cancer epithelium) |
Laser capture micro-dissected serous ovarian cancer epithelium cells derived from female individuals with primary papillary serous adenocarcinoma of the ovary. | |
Control | normal ovarian surface epithelium cell sample |
Normal ovarian surface epithelium cell (OSE) samples isolated from female individuals by laser capture micro-dissection (LCM). Indication for removal of healthy ovaries were others than ovary cancer. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)
Relative Expression (log2-ratio):-2.5733557Number of Samples:4 / 4
Experimental | B-CLL study 11 (rolipram) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
Control | rolipram study 4 (normal T-cell; 20uM) |
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)
Relative Expression (log2-ratio):-2.5521173Number of Samples:3 / 2
Experimental | prostate cancer study 8 (p. canc) |
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
Control | prostate cancer study 8 (ptasc) |
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
TNF-ɑ study 20 / normal monocyte sample
Relative Expression (log2-ratio):-2.5033379Number of Samples:3 / 7
Experimental | TNF-ɑ study 20 |
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. | |
Control | normal monocyte sample |
Monocyte samples isolated from healthy subjects. Peripheral blood monocytes were isolated immediately after drawing blood by depletion from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.491578Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |